The tactic may symbolize a fast and cheap approach to repurpose current therapies into new remedies for this progressive, debilitating neurodegenerative situation. Importantly, it may additionally assist reveal new, unexplored targets for remedy by pointing to mechanisms of drug motion.
“Repurposing FDA-approved medication for Alzheimer’s illness is a gorgeous concept that may assist speed up the arrival of efficient remedy — however sadly, even for beforehand authorized medication, medical trials require substantial assets, making it inconceivable to guage each drug in sufferers with Alzheimer’s illness,” mentioned researcher Artem Sokolov from
“We due to this fact constructed a framework for prioritising medication, serving to medical research to deal with probably the most promising ones,” Sokolov added.
For the examine, revealed in
DRIAD works by measuring what occurs to human mind neural cells when handled with a drug.
The tactic then determines whether or not the adjustments induced by a drug correlate with molecular markers of illness severity.
The method additionally allowed the researchers to determine medication that had protecting in addition to damaging results on mind cells.